YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
|
|
- Kristian Wood
- 5 years ago
- Views:
Transcription
1 Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: , ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline or systematic review indicate that the result is actionable in one or more of the following ways? Yes No Patient Management Surveillance or Screening 4. Is there at least one known pathogenic variant with at least moderate penetrance ( 40%) or moderate relative risk ( 2) in any population? UNKWN SIGNIFICANCE/BURDEN OF DISEASE 5. Is this condition an important health problem? Family Management Circumstances to Avoid ( 1 of above) NEXT STEPS 6. Are Actionability (Q2-3), Penetrance (Q4), and Significance (Q5) all? 3. Is the result actionable in an undiagnosed adult with the genetic condition? (Proceed to Stage II) (Consult Actionability Working Group) Exception granted, proceed to Stage II Exception not granted, STOP 1
2 GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome Topic Narrative Description of Evidence Ref Signif/Burden of Condition 1. What is the nature of the threat to health for an individual carrying a deleterious allele? Prevalence of the genetic disorder Clinical Features (Signs/symptoms) Natural History (Important subgroups & survival/recovery) Robust prevalence estimates for Juvenile polyposis syndrome (JPS) are not available because of its rarity, the lack of comprehensive clinical phenotype ascertainment and the fact that there are no population-based molecular studies. However, estimates of the population prevalence suggest the frequency of JPS may be similar to that of Peutz-Jeghers syndrome suggesting a frequency of around 1:50,000, although it may be as low as 1:120,000. JPS is characterized by predisposition to hamartomatous polyps in the gastrointestinal tract, specifically in the stomach, small intestine, colon, and rectum. Histological differences and topographical distribution within the gastrointestinal tract serve to distinguish between JPS and Peutz-Jeghers Syndrome. The number of polyps in individuals with JPS varies, with dozens to many hundreds of polyps present in the fully developed syndrome. A combined syndrome of JPS and hereditary hemorrhagic telangiectasia (HHT) (termed JPS/HHT) is present in most individuals with an SMAD4 pathogenic variant. [Hereditary hemorrhagic telangiectasia is addressed in a separate report] The term juvenile refers to the polyp type rather than to the age of onset, although most individuals with JPS have some polyps by 20 years of age. JPS usually manifests during childhood with polyps beginning to appear in the first decade of life. The average age at diagnosis is 18.5 years, but may be later, with rectal bleeding with anemia as the most common presenting symptom. Most juvenile polyps are benign; however, malignant transformation can occur. In those who develop cancer, the mean age of colon cancer is 34 years, with a range of 15 to 68 years and the median age of upper GI cancer is 58 years with a range of 21 to 73 years. 2. How effective are interventions for preventing the harm? Information on the effectiveness of the recommendations below was not provided unless otherwise stated. To determine the extent of disease, a baseline evaluation of patients should include a clinical history, complete blood count, colonoscopy, and upper endoscopy. (Tier 3) (1) Patient Management Surveillance Colectomy and ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis is indicated for polyp-related symptoms, or when the polyps cannot be managed endoscopically. One case series reported on long-term outcomes of colonic surgery in 13 patients presenting with symptomatic colon polyps (median age at diagnosis=10 years, range=1-50 years). Eight patients had their rectum removed during the study period; 5 had an ileal pouch-anal anastomosis, one had a Koch pouch as a restorative surgery, and 2 had an end ileostomy. No relation was observed between the number of colonic and rectal polyps and the type of surgery or the need for proctectomy. Patients were followed up a median of 3 years (range=2-24 years) after their ultimate operations. During this period, one patient (20%) who underwent restorative proctectomy and 4 patients (80%) whose rectums were preserved required multiple endoscopic polypectomies for recurrent polyps in the pouch (first patient) or their rectums (the other 4 patients). The patient who underwent the Koch procedure required surgery for recurrent polyps in her pouch.(tier 2) Colonoscopy is recommended in patients with JPS. Recommended starting age ranges across guidelines from 12-18, while frequency ranges from annually to every 3 years. The frequency of screening may be determined by the findings of the previous endoscopy, and may be extended to longer intervals after age 35. There are no comparative studies to demonstrate the potential benefit of screening; however, there is substantial risk of CRC in JPS patients. The life-time risk of CRC death in JPS patients not undergoing surveillance is (1, 2, 4, 5) 2
3 estimated to be as high as 1 in 6. ) One retrospective review of a registry of 44 patients with JPS undergoing routine surveillance (380 patient-years follow up) of the upper and lower GI tract has reported surveillance results. Screening detected 767 polyps and 20 adenomatous polyps. Five patients were identified requiring colorectal surgery. Two patients developed colorectal cancer while undergoing surveillance. However, given the lack of a control group it is unclear how many of these patients would have been detected clinically without undergoing surveillance.(tier 2) Family Management Circumstances to Avoid Upper endoscopy is also recommended in patients with JPS. Recommended starting age ranges across guidelines from years, while frequency ranges from annually to every 3 years. The frequency of screening is determined by the findings of the previous endoscopy, and may be extended to longer intervals after age 35. The risk of gastric and duodenal cancer in JPS is around 15-21%. Among the retrospective registry of JPS patients, gastrodueodenal polyps were found in 37% of patients and two patients were identified with adenomatous polyps of the stomach. Two patients were identified requiring gastrectomy. One patient developed cancer while undergoing surveillance. However, given the lack of a control group it is unclear how many of these patients would have been detected clinically without undergoing surveillance.(tier 2) Periodic enteroscopy, capsule endoscopy and/or CT enterography may be used for surveillance of the small intestine. (Tier 2) A case series of small-bowel capsule endoscopy of ten adults (median age 39.2 years) with documented JPS identified 2 patients that had small-bowel polyps beyond the range of standard gastroscopy identified at capsule endoscopy. Duodenal polyps were detected in a third patient at capsule endoscopy not previously detected by standard gastroscopy. However, given the lack of a control group it is unclear how many of these patients would have been detected clinically without undergoing surveillance (Tier 5) Genetic testing should be performed on at-risk family members in the first to second decade of life to identify those who will benefit from early surveillance intervention. (Tier 4) Relatives of individuals with an identified SMAD4 or BMPR1A pathologic variant who have not undergone molecular genetic testing or whose tests results were uninformative should undergo monitoring for stool change. In addition these patients should receive a complete blood count, colonoscopy and upper endoscopy starting in the mid-teens or at time of symptoms. The frequency of subsequent screening depends on the number of polyps identified on endoscopic screening. (Tier 3) For relatives not found to have a family specific genetic variant, CBC and lower initial endoscopy should be performed at age 15 years as a baseline screen, and if negative, repeated every ten years until age 45 after which time standard CRC screening recommendations may be followed. (Tier 3) None identified (1, 2, 4, 5) (2, 4) (6) Description of sources of evidence: Tier 1: Evidence from a systematic review, or a meta-analysis or clinical practice guideline clearly based on a systematic review Tier 2: Evidence from clinical practice guidelines or broad-based expert consensus with non-systematic evidence review Tier 3: Evidence from another source with non-systematic review of evidence with primary literature cited Tier 4: Evidence from another source with non-systematic review of evidence with no citations to primary data sources Tier 5: Evidence from a non-systematically identified source 3
4 GENE/GENE PANEL: DISORDER: Topic Narrative Description of Evidence Ref 3. What is the chance that this threat will materialize? Mode of Inheritance Autosomal Dominant Prevalence of Genetic Mutations No estimates were identified for the prevalence of SMAD4 or BMPR1A mutations. Up to 60% of individuals with a clinically defined JPS are found to exhibit mutations of the SMAD4 or BMPR1A genes.(tier 3) No studies have examined the proportion of individuals with known germline pathogenic variants for JPS who develop polyps. It is expected to be higher than 90%. (Tier 4) Penetrance OR Relative Risk (include high risk racial or ethnic subgroups) Estimates for the risk of colorectal cancer range from 10-68%, though a more recent synthesis estimates a range of 38-68%. (Tier 3) An estimated 21% of patients with JPS will develop upper gastrointestinal cancer. (Tier 3) (1, 2) The relative risk of developing colorectal cancer was found to be 34.0 (14.4 to 65.7). (Tier 3) Expressivity The number of polyps in individuals with JPS varies. Some individuals may have only four or five polyps over their lifetime; others in the same family may have more than 100. (Tier 4) 4. What is the nature of the intervention? Nature of Intervention Identified interventions include upper and lower gastrointestinal surveillance. 5. Would the underlying risk or condition escape detection prior to harm in the setting of recommended care? Chance to Escape Clinical Detection The average age at diagnosis is 18.5 years, but may be later, with rectal bleeding with anemia as the most common presenting symptom. (Tier 3) Final Consensus Scores Gene(s) Outcome/intervention pair Severity Likelihood Effectiveness Nature of the Intervention SMAD4 GI cancer/endoscopic surveillance 2 3C 3E 2 10CE To see the scoring key, please go to: Total Score 4
5 Date of Search: ( ) References 1. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5): Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. The American journal of gastroenterology. 2015;110:223-62; quiz Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. GeneReviews(R) National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal (Version ) 2015 [October 7, 2015]. Available from: 5. Scottish Intercollegiate Guidelines Network. Diagnosis and management of colorectal cancer. A national clinical guideline. Edinburgh (Scotland): 2011 no Postgate AJ, Will OC, Fraser CH, Fitzpatrick A, Phillips RK, Clark SK. Capsule endoscopy for the small bowel in juvenile polyposis syndrome: a case series. Endoscopy. 2009;41(11):
PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationPathology reports, related operative reports and consult letters must be provided with a request for assessment.
Page 1 of 6 Polyposis Syndromes Inherited risk for colorectal cancer is associated with a number of polyposis syndromes (genes), some of which are well-defined and others are less common. Identification
More informationYES NO UNKNOWN PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ATP7B DISORDER: Wilson Disease HGNC ID: 870 OMIM ID: 277900 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review,
More informationGI EMERGENCIES Acute Abdominal Pain
GI EMERGENCIES Acute Abdominal Pain Marcia Cruz-Correa, MD, PhD, AGAF. FASGE Associate Professor of Medicine, Biochemistry, Surgery Director Translational Research University of Puerto Rico Comprehensive
More informationGI Polyp syndromes in children. Screening and surveillance, surgery.
Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital, UK GI Polyp syndromes in children Screening and surveillance, surgery. No conflict of interests to declare Objectives Understand
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia HGNC ID: 3349, 175, 6770, 4217 OMIM ID: 187300, 600376, 175050, 615506 ACTIONABILITY
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 6998 OMIM ID: 134610 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationQuality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Efficiency DESCRIPTION:
More informationMichele Bettinelli RN Maria Scholz RN Sandra Scolaro RN
Michele Bettinelli RN Maria Scholz RN Sandra Scolaro RN Objectives Define Peutz-Jeghers Syndrome (PJS) Describe the management and treatment of PJS Discuss the patient experience associated with the diagnosis
More informationStage I: Rule-Out Dashboard Secondary Findings in Adults
Stage I: Rule-Out Dashboard GENE/GENE PANEL: DNM2 DISORDER: DNM2-Related Intermediate Charcot-Marie-Tooth Neuropathy HGNC ID: 2974 OMIM ID: 606482 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Syngal, MD, MPH, FACG, 1,2,3 Randall E. Brand, MD, FACG, 4 James M. Church, MD, FACG, 5,6,7
More information27
26 27 28 29 30 31 32 33 34 35 Diagnosis:? Diagnosis: Juvenile Polyposis with BMPR1A Mutation 36 Juvenile Polyposis Syndrome Rare Autosomal Dominant Disorder with Multiple Juvenile Polyps in GI Tract Juvenile
More informationFamilial Adenomatous Polyposis
Familial Adenomatous Polyposis 1 in 10,000 incidence 100 s to 1000 s of colonic adenomas by teens Cancer risk: colon, gastric, duodenum (periampulla), small bowel, pancreas, papillary thyroid, childhood
More informationResult Navigator. Positive Test Result: STK11. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: STK11 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationResult Navigator. Positive Test Result: BMPR1A. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: BMPR1A Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationClassification of polyposis syndromes two major groups. Adenomatous polyposis syndromes. Hamartomatous polyposis syndromes
Hereditary polyposis syndromes Classification of polyposis syndromes two major groups adenomatous and non-adenomatous polyposis syndromes Adenomatous polyposis syndromes Familial adenomatous polyposis(fap)
More informationcolorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018
colorectal cancer Adenocarcinoma of the colon and rectum is the third most common site of new cancer cases and deaths in men (following prostate and lung or bronchus cancer) and women (following breast
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationAn Introduction to MUTYH Associated Polyposis (MAP)
An Introduction to MUTYH Associated Polyposis (MAP) 1 An Introduction to MUTYH Associated Polyposis(MAP) Contents What is MUTYH Associated Polyposis (MAP)? 2 What causes MUTYH Associated Polyposis (MAP)?
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TNNT2, LMNA HGNC ID: 11949, 6636 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition?
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2019 Origination: 1/2004 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas
More informationHereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD
Hereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD Living Beyond Cancer A-Z January 12,2019 Hereditary CRC Syndromes Objectives are to discuss the : Most common Hereditary CRC syndromes
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationStage I: Rule-Out Dashboard
Stage I: Rule-Out Dashboard GENE/GENE PANEL: GLA DISORDER: Fabry disease HGNC ID: 4296 OMIM ID: 301500 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic
More informationJOURNAL OF CASE REPORTS 2014;4(2):
JOURNAL OF CASE REPORTS 2014;4(2):395-399 Juvenile Polyposis Syndrome -Two Case Reports Samuel Essoun 1, Jonathan CB Dakubo 2, Antoinette A Bediako-Bowan 2 From the Department of Surgery, 1 Korle Bu Teaching
More informationStage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
More informationEndoscopic techniques for surveillance and treatment of FAP
Endoscopic techniques for surveillance and treatment of FAP Evelien Dekker MD PhD Department of Gastroenterology & Hepatology Academic Medical Center Amsterdam The Netherlands FAP: endoscopic surveillance
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 11949, 6636, 2928 OMIM ID: 191045, 150330, 302045 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationBowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:
BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK. Unfortunately 1 in 19 women and 1 in 14 men will develop
More informationPMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table
PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationOPEN ACCESS TEXTBOOK OF GENERAL SURGERY
OPEN ACCESS TEXTBOOK OF GENERAL SURGERY COLORECTAL POLYPS P Goldberg POLYP A polyp is a localised elevated lesion arising from a epithelial surface. If it has a stalk it is called a pedunculated polyp
More informationColorectal Cancer Syndromes. Barbara Jung, MD AGAF Associate Professor and Chief University of Illinois at Chicago
Colorectal Cancer Syndromes Barbara Jung, MD AGAF Associate Professor and Chief University of Illinois at Chicago Outline Colon cancer General Genetics, Risk, Screening Specific Syndromes, when to suspect,
More informationGHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene
GHUK BowelGene_2017.qxp_Layout 1 22/02/2017 10:22 Page 3 BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK.
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 9585 OMIM ID: 109400 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationMSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table
MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationGI Screening/Surveillance in Lynch Syndrome
GI Screening/Surveillance in Lynch Syndrome M Appleyard Royal Brisbane and Women s Hospital Brisbane, Australia GI Disease and Lynch Syndrome What are risks of GI disease in Lynch? Who do we screen for
More informationAccepted Manuscript. Utility of Genetic Testing in Persons with Multiple Colorectal Polyps. Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS
Accepted Manuscript Utility of Genetic Testing in Persons with Multiple Colorectal Polyps Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS PII: S1542-3565(19)30259-9 DOI: https://doi.org/10.1016/j.cgh.2019.03.007
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationThe term juvenile polyp was used in 1957 by Horrilleno. Juvenile Polyps: Recurrence in Patients With Multiple and Solitary Polyps
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:795 799 Juvenile Polyps: Recurrence in Patients With Multiple and Solitary Polyps VICTOR L. FOX,* STEPHEN PERROS,* HONGYU JIANG,*, and JEFFREY D. GOLDSMITH,
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More informationColorectal Cancer and Hereditary Colon Cancer Syndromes Carol A. Burke, M.D.
Colorectal Cancer and Hereditary, FACG, FACP Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia Digestive Disease Institute Cleveland Clinic, Cleveland, Ohio 1 Objectives Review the molecular
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More informationPeutz Jegher's Syndrome (Gastro-intestinal Polyposis) and Its Complications
Peutz Jegher's Syndrome (Gastro-intestinal Polyposis) and Its Complications Pages with reference to book, From 154 To 155 Zakiuddin G. Oonwala, Sina Aziz ( Department of Surgery, Dow Medical College and
More informationHereditary GI tumor syndromes ACG guidelines of genetic testing and management. Dr. med. Henrik Csaba Horváth PhD
Hereditary GI tumor syndromes ACG guidelines of genetic testing and management Dr. med. Henrik Csaba Horváth PhD Genetic testing and management of hereditary GI tumor syndromes June 29, 2016 2 Clinical
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationDisclosure. Polyps in Pediatrics. Learning Objectives. Case Presentation I. Case Presentation II
Disclosure Polyps in Pediatrics I have no relationships with commercial companies to disclose. Sonal Desai, MD Division of Pediatric Gastroenterology May 31, 2013 Pediatric Grand Rounds Learning Objectives
More informationColon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011
Colon Cancer Screening and Surveillance Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011 Colorectal Cancer Preventable cancer Number 2 cancer killer in the USA Often curable if detected
More informationMLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table
MLH1 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Cancer (HNPCC) MLH1 Summary Cancer Risk Table CANCER GENETIC CANCER RISK Endometrial Other MLH1 gene Overview Lynch syndrome 1,
More informationIs Colonoscopy Necessary in Children Suspected of Having Colonic Polyps?
Gut and Liver, Vol. 4, No. 3, September 2010, pp. 326-331 original article Is Colonoscopy Necessary in Children Suspected of Having Colonic Polyps? Hye Jin Lee, Ji Hyuk Lee, Jong Seung Lee, and Yon Ho
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationHereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management
CLINICAL AND SYSTEMATIC S 1509 CME Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management Pr iyan ka Kant h, M D, M S 1, Jade Grimmett, MS2, 3, Mar j an C hampi ne,
More informationDigestive Disease Institute. Clinical Research. Discovering New Ways to Diagnose and Treat Digestive Diseases
Digestive Disease Institute Clinical Research Discovering New Ways to Diagnose and Treat Digestive Diseases What Is A Clinical Trial? A clinical trial is a scientific study designed to assess whether a
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TTR DISORDER: Hereditary transthyretin-related amyloidosis HGNC ID: 12405 OMIM ID: 105210 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationUpdate on Hereditary Gastric Cancer. Dr. Savtaj Brar MD MSc Surgical Oncologist Assistant Professor of Surgery
Update on Hereditary Gastric Cancer Dr. Savtaj Brar MD MSc Surgical Oncologist Assistant Professor of Surgery Disclosures None Outline 1. Discuss new consensus guidelines on hereditary diffuse gastric
More informationCOLON CANCER SCREENING IN CYSTIC FIBROSIS
COLON CANCER SCREENING IN CYSTIC FIBROSIS Laveena Chhatwani, MD, MSc Associate Director, Adult Cystic Fibrosis Program Clinical Assistant Professor of Medicine Outline Background Risk of colorectal cancer
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Colon polyps Colorectal cancer Harrison s Principles of Internal Medicine 18 Ed. 2012 Colorectal cancer 70% Colorectal cancer CRC and colon
More informationRare presentation of Recurrent Multiple Intussusceptions in a case of Post Total Colectomy for Peutz-Jeghers Polyposis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 3 Ver. VIII (Mar. 2015), PP 06-10 www.iosrjournals.org Rare presentation of Recurrent Multiple
More informationA Patient s Guide to risk assessment. Hereditary Colorectal Cancer
A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? Overview of Syndromes This workbook is designed to help you decide if hereditary cancer
More informationA superficial radiotherapy B single pass curettage C excision with 2 mm margins D excision with 5 mm margins E Mohs micrographic surgery.
1- A 63-year-old woman presents with a non-healing lesion on her right temple that has been present for over two years. On examination there is a 6 mm well defined lesion with central ulceration, telangiectasia
More informationPathology perspective of colonic polyposis syndromes
Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding
ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding Lauren B. Gerson, MD, MSc, FACG 1, Jeff L. Fidler 2, MD, David R. Cave, MD, PhD, FACG 3, Jonathan A. Leighton, MD, FACG 4 1 Division
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More informationDIGESTIVE SYSTEM SURGICAL PROCEDURES May 1, 2015 INTESTINES (EXCEPT RECTUM) Asst Surg Anae
ENDOSCOPY Z50 Duodenoscopy (not to be claimed if Z399 and/or Z00 performed on same patient within 3 months)... 92.10 Z9 Subsequent procedure (within three months following previous endoscopic procedure)...
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationHereditary Colorectal Cancer
A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: LMNA, EMD, FHL1 DISORDER: Emery-Dreifuss Muscular Dystrophy (AD, XL) HGNC ID: 6636, 3331, 3702 OMIM ID: 181350, 310300, 300696 ACTIONABILITY PENETRANCE 1. Is
More informationAppendix 1 (as supplied by the authors): Supplementary tables. Supplementary Table A1. Description of OHIP codes used in the current study.
Appendix 1 (as supplied by the authors): Supplementary tables Supplementary Table A1. Description of OHIP codes used in the current study. OHIP Billing Code OHIP Billing Code Description Colonoscopy and
More informationCLINICAL FOCUS. Juvenile Polyposis. Winter 2009
CLINICAL FOCUS Juvenile Polyposis Carol Durno, MD, MSc Registry Pediatric Gastroenterologist People can have many polyps in the gastrointestinal tract. The type and number of polyps found help determine
More informationFAMILIAL ADENOMATOUS POLYPOSIS (COLORECTAL CANCER) PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES
FAMILIAL ADENOMATOUS POLYPOSIS (COLORECTAL CANCER) PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES Coordinator: Alex Kartheuser (Colorectal Surgery, Cliniques universitaires St-Luc, UCL) Authors
More informationHeather Hampel, MS, CGC Professor, Division of Human Genetics
Familial, Hereditary, and Early Age Onset Colorectal Cancer: A Module Designed to Assist Primary Care Clinician s in the Identification of Individuals at Increased Risk and Facilitate Earliest Possible
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More informationGastrointestinal polyposis syndromes for the general gastroenterologist
TRAINING MATTERS CURRICULUM BASED CLINICAL REVIEWS Gastrointestinal polyposis syndromes for the general gastroenterologist Joanna J Hurley, 1,2 Iain Ewing, 3 Julian R Sampson, 2 Sunil Dolwani 1 1 Department
More information